Urigen Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urigen’s product development programs target significant unmet medical needs and major market opportunities in urology. URG101 targets painful bladder syndrome/interstitial cystitis, which affects approximately 10.5 million men and women in North America. URG201 targets male hypogonadism, which has been estimated to effect 13 million men in the Untied States. Urigen’s URG301 project targets urethritis and acute urgency in patients diagnosed with an overactive bladder. For further information, please visit Urigen’s website at http://www.urigen.com.

Contact Information

875 Mahler Road
Suite 235
Burlingame, CA 94010

tel: 650-259-0239
fax: (415) 652-1990


Investor Relations



Exchange: OTCBB
Industry: Unknown
Market Cap: $9M

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.